Novira Therapeutics

company

About

Novira Therapeutics is an antiviral drug discovery company discovering antiviral therapeutics to treat HBV and HIV infections.

  • 11 - 50

Details

Last Funding Type
Series A
Last Funding Money Raised
$25M
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2009
Number Of Employee
11 - 50
Operating Status
Active

Novira Therapeutics is an antiviral drug discovery company that is focused on the discovery of first-in-class antiviral therapeutics for the treatment of chronic HBV and HIV infections, two global diseases with high levels of unmet need. Novira’s oral drugs target the capsid of the virus, and offer a promising treatment option both as monotherapy and in combination with current standards of care. The company’s antivirals potentially address limitations in treating chronic HBV infection, a disease for which the only class of oral drugs available, polymerase inhibitors, are rarely curative and often require lifelong treatment, as well as in chronic HIV infection, a disease for which the continued ability of the virus to mutate inevitably leads to drug-resistant viral strains. Each of these limitations to the standard of care can potentially be addressed by capsid inhibitors which feature a new mechanism of action.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$25M
Novira Therapeutics has raised a total of $25M in funding over 2 rounds. Their latest funding was raised on Mar 24, 2013 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 24, 2013 Series A $25M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Novira Therapeutics is funded by 1 investors. Versant Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Versant Ventures Series A